What is HC Wainwright’s Forecast for Metagenomi Q4 Earnings?

Metagenomi, Inc. (NASDAQ:MGX) – Investment analysts at HC Wainwright increased their Q4 2024 earnings per share (EPS) estimates for Metagenomi in a research note issued on Thursday, November 21st. HC Wainwright analyst M. Kapoor now expects that the company will post earnings of ($0.52) per share for the quarter, up from their previous forecast of ($0.69). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Metagenomi’s current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Metagenomi’s Q1 2025 earnings at ($0.56) EPS, Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.65) EPS, Q4 2025 earnings at ($0.69) EPS and FY2025 earnings at ($2.48) EPS.

Other equities research analysts have also issued reports about the stock. Chardan Capital reiterated a “buy” rating and set a $15.00 price target on shares of Metagenomi in a research note on Wednesday, November 20th. BMO Capital Markets cut their target price on Metagenomi from $22.00 to $17.00 and set an “outperform” rating on the stock in a research report on Thursday, August 15th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Metagenomi has an average rating of “Moderate Buy” and an average price target of $15.50.

Metagenomi Stock Performance

Shares of NASDAQ:MGX opened at $2.01 on Monday. Metagenomi has a twelve month low of $1.61 and a twelve month high of $12.74. The firm has a 50 day simple moving average of $2.06 and a 200-day simple moving average of $3.67.

Institutional Investors Weigh In On Metagenomi

Several hedge funds have recently modified their holdings of the stock. Rhumbline Advisers purchased a new stake in shares of Metagenomi in the second quarter valued at about $26,000. BNP Paribas Financial Markets increased its position in Metagenomi by 130.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,799 shares of the company’s stock worth $28,000 after purchasing an additional 7,256 shares during the period. Virtu Financial LLC purchased a new position in shares of Metagenomi during the 3rd quarter worth approximately $33,000. XTX Topco Ltd acquired a new stake in shares of Metagenomi in the 2nd quarter valued at approximately $66,000. Finally, Resolute Advisors LLC boosted its stake in shares of Metagenomi by 165.0% in the second quarter. Resolute Advisors LLC now owns 26,500 shares of the company’s stock valued at $108,000 after buying an additional 16,500 shares in the last quarter.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.